- Home
- MTAL vs ELVN Comparison
MTAL vs ELVN Comparison
Compare MTAL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- ELVN
- Stock Information
- Founded
- MTAL 2021
- ELVN 2016
- Country
- MTAL Jersey
- ELVN United States
- Employees
- MTAL 3
- ELVN 57
- Industry
- MTAL Blank Checks
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- ELVN Health Care
- Exchange
- MTAL Nasdaq
- ELVN Nasdaq
- Market Cap
- MTAL 886.2M
- ELVN 1.1B
- IPO Year
- MTAL 2021
- ELVN 2020
- Fundamental
- Price
- MTAL $10.75
- ELVN $21.80
- Analyst Decision
- MTAL Buy
- ELVN Strong Buy
- Analyst Count
- MTAL 2
- ELVN 5
- Target Price
- MTAL $14.75
- ELVN $37.80
- AVG Volume (30 Days)
- MTAL 219.7K
- ELVN 224.0K
- Earning Date
- MTAL 01-01-0001
- ELVN 03-13-2025
- Dividend Yield
- MTAL N/A
- ELVN N/A
- EPS Growth
- MTAL N/A
- ELVN N/A
- EPS
- MTAL N/A
- ELVN N/A
- Revenue
- MTAL $322,583,000.00
- ELVN N/A
- Revenue This Year
- MTAL $126.93
- ELVN N/A
- Revenue Next Year
- MTAL $19.58
- ELVN N/A
- P/E Ratio
- MTAL N/A
- ELVN N/A
- Revenue Growth
- MTAL 1636.56
- ELVN N/A
- 52 Week Low
- MTAL $9.89
- ELVN $10.90
- 52 Week High
- MTAL $15.26
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- MTAL 46.46
- ELVN 48.03
- Support Level
- MTAL $10.84
- ELVN $21.16
- Resistance Level
- MTAL $11.60
- ELVN $22.91
- Average True Range (ATR)
- MTAL 0.34
- ELVN 1.00
- MACD
- MTAL 0.03
- ELVN 0.06
- Stochastic Oscillator
- MTAL 49.01
- ELVN 45.02
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.